Rapport Therapeutics (NASDAQ: RAPP) net income
Rapport Therapeutics reported a net loss of $111.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $78.3m. Earnings per share were −$2.86.
Rapport Therapeutics's best year of the last 3 was fiscal 2023. It reported a loss in 3 of those 3 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$111.5m | — | — | −$2.86 |
| 2024 | −$78.3m | — | — | −$3.78 |
| 2023 | −$34.8m | — | — | −$23.10 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Rapport Therapeutics net income compared with its sector
By net income for its latest fiscal year, Rapport Therapeutics ranks 347th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 345th | NeoGenomics | −$108.0m | −14.9% |
| 346th | Taysha Gene Therapies | −$109.0m | −1,115.3% |
| 347th | Rapport Therapeutics | −$111.5m | — |
| 348th | Janux Therapeutics | −$113.6m | −1,136.3% |
| 349th | IDEAYA Biosciences | −$113.7m | −52.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Rapport Therapeutics
- How much did Rapport Therapeutics earn in fiscal 2025?
- Rapport Therapeutics reported a net loss of $111.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $78.3m.
- What are the earnings per share of Rapport Therapeutics?
- They were −$2.86 in fiscal 2025, compared with −$3.78 in fiscal 2024.
- Where does Rapport Therapeutics rank in its sector by net income?
- It ranks 347th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Rapport Therapeutics come from?
- From the annual report (Form 10-K) that Rapport Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Rapport Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Rapport Therapeutics: the Rapport Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.